Home / Therapies / SGLT-2 Therapy Center (page 12)

SGLT-2 Therapy Center

Diabetes in Control is pleased to provide you with the latest insights and information on the Sodium-Dependent Glucose Transporter Two (SGLT-2) drug class to help optimize your practice. We hope you’ll benefit from the insights and share them with your colleagues. Thanks for all you’re doing to improve your patients’ lives and longevity!

Did You Know: What Are the SGLT-2 Inhibitor Trade-offs?

The overall profile of sodium-glucose cotransporter 2 inhibitors suggests they are a reliable, second-line therapy choice for adults with type 2 diabetes. However, the class is associated with possible side effects that should be carefully considered, according to a Dr. George L. Bakris, MD, director of the ASH Comprehensive Hypertension Center at the University of Chicago Medicine at a recent presentation at the Cardiometabolic Health Congress. Dr. Bakris stated that they definitely are preferred second-line agents, absolutely over sulfonylureas, and probably over thiazolidinediones and some other agents as well.

Read More »